Skip to main content

Reviews from Journal of Experimental & Clinical Cancer Research

Below is a summary of all reviews published in JECCR

Page 1 of 7

  1. Cell division cycle 20 homologue (CDC20) is a well-known regulator of cell cycle, as it controls the correct segregation of chromosomes during mitosis. Many studies have focused on the biological role of CDC20...

    Authors: Samantha Bruno, Andrea Ghelli Luserna di Rorà, Roberta Napolitano, Simona Soverini, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:159
  2. Metabolites are intermediate products of cellular metabolism catalysed by various enzymes. Metabolic remodelling, as a biochemical fingerprint of cancer cells, causes abnormal metabolite accumulation. These me...

    Authors: Yidian Fu, Jie Yu, Fang Li and Shengfang Ge
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:144
  3. Cancer cells can evade immune responses by exploiting inhibitory immune checkpoints. Immune checkpoint inhibitor (ICI) therapies based on anti-CTLA-4 and anti-PD-1/PD-L1 antibodies have been extensively explor...

    Authors: Andreia Peixoto, Andreia Miranda, Lúcio Lara Santos and José Alexandre Ferreira
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:143
  4. The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by pathogen-associated molecular pat...

    Authors: Austin P. Runde, Ryan Mack, Peter Breslin S.J. and Jiwang Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:135
  5. Cholangiocarcinoma (CCA) is the second most common primary liver cancer and associated with a dismal prognosis due to the lack of an efficient systemic therapy. In contrast to other cancers, new immunotherapie...

    Authors: Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann and Jan Bednarsch
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:127
  6. Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies. H...

    Authors: Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu, Huihong Xu, Chong-xian Pan and Zheng Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:119
  7. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, being the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death. As other heterogeneous solid tumou...

    Authors: Maria Rita Braghini, Oriana Lo Re, Ilaria Romito, Maite G. Fernandez-Barrena, Barbara Barbaro, Silvia Pomella, Rossella Rota, Manlio Vinciguerra, Matias A. Avila and Anna Alisi
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:107
  8. Prostate cancer is a leading cause of death worldwide and new estimates revealed prostate cancer as the leading cause of death in men in 2021. Therefore, new strategies are pertinent in the treatment of this m...

    Authors: Milad Ashrafizadeh, Mahshid Deldar Abad Paskeh, Sepideh Mirzaei, Mohammad Hossein Gholami, Ali Zarrabi, Farid Hashemi, Kiavash Hushmandi, Mehrdad Hashemi, Noushin Nabavi, Francesco Crea, Jun Ren, Daniel J. Klionsky, Alan Prem Kumar and Yuzhuo Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:105
  9. DNA methylation is one of the most important epigenetic mechanisms to regulate gene expression, which is highly dynamic during development and specifically maintained in somatic cells. Aberrant DNA methylation...

    Authors: Wanxu Huang, Hua Li, Qingsong Yu, Wei Xiao and Dan Ohtan Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:100
  10. Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitat...

    Authors: Afsheen Raza, Abdul Q. Khan, Varghese Philipose Inchakalody, Sarra Mestiri, Zeenath Safira K. M. Yoosuf, Takwa Bedhiafi, Dina Moustafa Abo El-Ella, Nassiba Taib, Shereena Hydrose, Shayista Akbar, Queenie Fernandes, Lobna Al-Zaidan, Roopesh Krishnankutty, Maysaloun Merhi, Shahab Uddin and Said Dermime
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:99
  11. The cohesin complex controls faithful chromosome segregation by pairing sister chromatids after DNA replication until mitosis. In addition, it is crucial for hierarchal three-dimensional organization of the ge...

    Authors: Maddalena Di Nardo, Maria M. Pallotta and Antonio Musio
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:96
  12. Neuroblastoma (NB) is a pediatric tumor that originates from neural crest-derived cells undergoing a defective differentiation due to genomic and epigenetic impairments. Therefore, NB may arise at any final si...

    Authors: Mirco Ponzoni, Tiziana Bachetti, Maria Valeria Corrias, Chiara Brignole, Fabio Pastorino, Enzo Calarco, Veronica Bensa, Elena Giusto, Isabella Ceccherini and Patrizia Perri
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:92
  13. Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity. Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) ...

    Authors: Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal and Purificación Muñoz
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:62
  14. Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell deat...

    Authors: Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang and Xueli Bai
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:56
  15. Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activati...

    Authors: Lina Merkens, Verena Sailer, Davor Lessel, Ella Janzen, Sarah Greimeier, Jutta Kirfel, Sven Perner, Klaus Pantel, Stefan Werner and Gunhild von Amsberg
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:46
  16. Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. ...

    Authors: Mathilde Bausart, Véronique Préat and Alessio Malfanti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:35
  17. The role of the microbiota in human health and disease is well established, including its effects on several cancer types. However, the role of microbial dysbiosis in prostate cancer development, progression, ...

    Authors: Paul Vinu Salachan and Karina Dalsgaard Sørensen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:31
  18. The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After decades of research, in 2013, the Shokat lab achieved a seminal...

    Authors: Albert K. Kwan, Gary A. Piazza, Adam B. Keeton and Caio A. Leite
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:27
  19. Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a distinctive tumor microenvironment (TME) and a unique spectrum of mutations. Despite the important therapeutic ad...

    Authors: Rada Amin and Mounia S. Braza
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:21
  20. The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is...

    Authors: Tal Flieswasser, Astrid Van den Eynde, Jonas Van Audenaerde, Jorrit De Waele, Filip Lardon, Carsten Riether, Hans de Haard, Evelien Smits, Patrick Pauwels and Julie Jacobs
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:12
  21. micro(mi)RNAs are short noncoding RNAs that through their seed sequence (pos. 2–7/8 of the guide strand) regulate cell function by targeting complementary sequences (seed matches) located mostly in the 3′ untr...

    Authors: Ashley Haluck-Kangas, Monal Patel, Bidur Paudel, Aparajitha Vaidyanathan, Andrea E. Murmann and Marcus E. Peter
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:389
  22. Short or small interfering RNAs (siRNAs) and microRNA (miRNAs) are molecules similar in size and function able to inhibit gene expression based on their complementarity with mRNA sequences, inducing the degrad...

    Authors: Rossana Cuciniello, Stefania Filosa and Stefania Crispi
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:383

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2021 40:403

  23. Despite  improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused a...

    Authors: Hussein Ghamlouch, Eileen M. Boyle, Patrick Blaney, Yubao Wang, Jinyoung Choi, Louis Williams, Michael Bauer, Daniel Auclair, Benedetto Bruno, Brian A. Walker, Faith E. Davies and Gareth J. Morgan
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:380
  24. Nonsense-mediated mRNA decay (NMD) is a highly conserved cellular surveillance mechanism, commonly studied for its role in mRNA quality control because of its capacity of degrading mutated mRNAs that would pro...

    Authors: Roberta Bongiorno, Mario Paolo Colombo and Daniele Lecis
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:376
  25. Breast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and ...

    Authors: Cenzhu Wang, Kun Xu, Runtian Wang, Xin Han, Jinhai Tang and Xiaoxiang Guan
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:370
  26. Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the U...

    Authors: Xinyi Xiao, Shengkang Huang, Sifei Chen, Yazhuo Wang, Qihang Sun, Xinjie Xu and Yuhua Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:367
  27. Protein ubiquitination is one of the most crucial posttranslational modifications responsible for regulating the stability and activity of proteins involved in homeostatic cellular function. Inconsistencies in...

    Authors: Ravi Chauhan, Ajaz A. Bhat, Tariq Masoodi, Puneet Bagga, Ravinder Reddy, Ashna Gupta, Zahoor Ahmad Sheikh, Muzafar A. Macha, Mohammad Haris and Mayank Singh
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:356
  28. The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only ha...

    Authors: Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. Zamyatnin Jr and Surinder M. Soond
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:355
  29. Disordered chromatin remodeling regulation has emerged as an essential driving factor for cancers. Imitation switch (ISWI) family are evolutionarily conserved ATP-dependent chromatin remodeling complexes, whic...

    Authors: Yanan Li, Han Gong, Pan Wang, Yu Zhu, Hongling Peng, Yajuan Cui, Heng Li, Jing Liu and Zi Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:346
  30. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric...

    Authors: Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li and Guang Liang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:345
  31. Mounting evidence indicates that vitamin C has the potential to be a potent anti-cancer agent when administered intravenously and in high doses (high-dose IVC). Early phase clinical trials have confirmed safet...

    Authors: Franziska Böttger, Andrea Vallés-Martí, Loraine Cahn and Connie R. Jimenez
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:343
  32. Epithelial ovarian cancer (EOC) harbors distinct genetic features such as homologous recombination repair (HRR) deficiency, and therefore may respond to poly ADP-ribose polymerase inhibitors (PARPi). Over the ...

    Authors: Mengyu Tao and Xia Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:338
  33. Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understandin...

    Authors: Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li and Peng Cao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:331
  34. Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8...

    Authors: Jing Zhou, Qing Ji and Qi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:328
  35. The efficacy of cancer immunotherapy largely depends on the tumor microenvironment, especially the tumor immune microenvironment. Emerging studies have claimed that microbes reside within tumor cells and immun...

    Authors: Jiayao Ma, Lingjuan Huang, Die Hu, Shan Zeng, Ying Han and Hong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:327
  36. Despite the overall clinical success of immune checkpoint inhibitors (ICIs) for treating patients with solid tumors, a large number of patients do not benefit from this approach. Consequently, there is a need ...

    Authors: Christina Jensen, Neel I. Nissen, Claus S. Von Arenstorff, Morten A. Karsdal and Nicholas Willumsen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:326
  37. Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to r...

    Authors: Carol Moreno, Cecilia Muñoz, María José Terol, José-Ángel Hernández-Rivas and Miguel Villanueva
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:321
  38. The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the develop...

    Authors: Vincent Lemaire, Colby S. Shemesh and Anand Rotte
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:311
  39. Kidney cancer is a common urological tumour. Owing to its high prevalence and mortality rate, it is the third most malignant tumour of the urinary system, followed by prostate and bladder cancers. It exerts a ...

    Authors: Weipu Mao, Keyi Wang, Zonglin Wu, Bin Xu and Ming Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:305
  40. The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the over...

    Authors: Taofei Zeng, Yuqing Cao, Tianqiang Jin, Yu Tian, Chaoliu Dai and Feng Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:285
  41. Epithelial ovarian cancer (EOC) is the most common gynecologic disorder. Even with the recent progresses made towards the use of new therapeutics, it still represents the most lethal gynecologic malignancy in ...

    Authors: Delphine Fessart, Jacques Robert, Cecile Hartog, Eric Chevet, Frederic Delom and Guillaume Babin
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:271
  42. Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeu...

    Authors: Sasan Ghaffari, Nastaran Khalili and Nima Rezaei
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:269
  43. Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-surface molecules that control immune cell responses by either promoting (costimulatory molecules) or inhibiting (coinhibitory...

    Authors: Baokang Wu, Chongli Zhong, Qi Lang, Zhiyun Liang, Yizhou Zhang, Xin Zhao, Yang Yu, Heming Zhang, Feng Xu and Yu Tian
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:267
  44. Autophagy is an intracellular degradation system that removes unnecessary or dysfunctional components and recycles them for other cellular functions. Over the years, a mutual regulation between lipid metabolis...

    Authors: Francesca Ascenzi, Claudia De Vitis, Marcello Maugeri-Saccà, Christian Napoli, Gennaro Ciliberto and Rita Mancini
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:265
  45. Tumor resistance to apoptosis and the immunosuppressive tumor microenvironment are two major contributors to poor therapeutic responses during cancer intervention. Pyroptosis, a lytic and inflammatory programm...

    Authors: Reid Loveless, Ryan Bloomquist and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:264
  46. Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) gain a novel function for the conversion of α-ketoglutarate (α-KG) to oncometabolite R-2-hydroxyglutarate (R-2-HG). Two molecular entities namely enasidenib (AG-221) ...

    Authors: Kun Yao, Hua Liu, Jiajun Yin, Jianmin Yuan and Hong Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:263